Sanofi recalls auto-injector epinephrine pens used for allergic reactions

In its third-quarter global financial results released Thursday, Paris-based Sanofi said that the recall of its epinephrine injectors may end up wiping 100 million euros ($145 million) off its bottom line.

Sanofi is recalling the drug over concerns that it potentially injects “inaccurate dosage delivery”, which includes not receiving enough of the medication at once.

Sanofi is recalling hundreds of thousands of epinephrine injectors used to treat severe allergic reactions because they may not deliver the correct amount of the life-saving drug.

Sanofi has issued a voluntary recall of all 490,000 Auvi-Q injectors now on the market – both the 0.15 mg and 0.3 mg strengths designed for hospitals, retailers, and consumers.

The company pledged to reimburse customers for out-of-pocket costs incurred when buying a new auto-injector with proof of purchase.

As of October 26, 2015, the company has received 26 reports of suspected device malfunctions in the USA and Canada.

Sanofi’s product competes with Mylan’s EpiPen, which is a staple of first-aid care.

The company asks Canadian customers to take Allerjects to their local pharmacy to be replaced with an alternative epinephrine auto-injector.

Auvi-Q said anyone who has the drug should immediately get a new epinephrine pen by another company.

The product is packaged with two active devices and one trainer device in a corrugate box, and was distributed throughout the USA via wholesalers, pharmacies and hospitals.

Consumers with questions regarding this recall can go to www.Auvi-Q.com or call 1-866-726-6340 Monday through Friday 8 a.m.to 8 p.m. (ET) for information about how to return their Auvi-Q devices.